Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

AZD1152

1200 mg, iv, 7 day infusion

DRUG

LDAC

20 mg, sc, bd, 10 days

Trial Locations (45)

Unknown

Research Site, Atlanta

Research Site, Chicago

Research Site, New York

Research Site, Cleveland

Research Site, Portland

Research Site, Greenville

Research Site, Nashville

Research Site, Houston

Research Site, Westmead

Research Site, Herston

Research Site, Melbourne

Research Site, Parkville

Research Site, Angers

Research Site, Clermont-Ferrand

Research Site, Grenoble

Research Site, Lyon

Research Site, Marseille

Research Site, Nantes

Research Site, Duisburg

Research Site, Erlangen

Research Site, Frankfurt

Research Site, Münster

Research Site, Villingen-Schwenningen

Research Site, Bologna

Research Site, Genova

Research Site, Orbassano

Research Site, Udine

Research Site, Roma

Research Site, Nagoya

Research Site, Yoshida-gun

Research Site, Maebashi

Research Site, Isehara

Research Site, Yokohama

Research Site, Chūō

Research Site, Fukuoka

Research Site, Brasov

Research Site, TG Mures

Research Site, Badalona(barcelona)

Research Site, Barcelona

Research Site, Madrid

Research Site, Majadahonda

Research Site, Oviedo

Research Site, Valencia

Research Site, Brighton

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY